How much funding has Jounce Therapeutics raised?

Jounce Therapeutics has raised $56.0M in total funding, most recently a Series B round.

When was Jounce Therapeutics founded?

Jounce Therapeutics was founded in 2013.

Where is Jounce Therapeutics headquartered?

Jounce Therapeutics is headquartered in Cambridge, United States.

What industry is Jounce Therapeutics in?

Jounce Therapeutics operates in Biotech.

How many employees does Jounce Therapeutics have?

Jounce Therapeutics has 51-200 employees.

Jounce Therapeutics

Q: Who are Jounce Therapeutics's investors?

Jounce Therapeutics's investors include Casdin Capital, Fidelity Management, Foresite Capital, Omega Funds.

Closed

Daring to create a world immune to cancer.

Cambridge, United States · Founded 2013 · $56.0M raised

Biotech

Headquarters: Cambridge
Employees: 51–200
Founded: 2013
Business Model: B2B

Website: jouncetx.com
Total Funding: $56.0M
Last Round: $56.0M Series BApr 2015
Rounds: 2

About

Jounce Therapeutics, Inc. is a clinical-stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable a patient's immune system to combat tumors. Founded in 2013 by world leaders in immunobiology, cancer biology, and clinical and translational medicine, including Richard Murray, Gordon Freeman, and Glenn Dranoff, the company launched with backing from Third Rock Ventures. Jounce's research is grounded in translational science that identifies patient subsets most likely to respond to immunotherapy combinations.

Summary

Jounce Therapeutics is a Biotech company based in Cambridge, United States, founded in 2013. It has raised $56.0M in total across 2 rounds, most recently a $56.0M Series B round in Apr 2015. Investors include Casdin Capital, Fidelity Management and Foresite Capital.